why did jaguar health stock drop

To top it all off, the stock closed its first day of trading at $6.78, down about 3% from the already lowered offering price. Unhappily, Jaguar Health had to report a 28% decline in EPS over the last year. SAN FRANCISCO --(BUSINESS WIRE)--Nov. 7, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, Site Provides Information and Resources for Consumers as Well as HIV Physicians, Gastroenterologists and Other Healthcare Professionals SAN FRANCISCO --(BUSINESS WIRE)--Nov. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and, Campaign Kicks Off with Events at AIDS Walk Los Angeles and Greater Palm Springs Pride as Well as Digital Ads on More Than 25 HIV/LGBT Media Outlets SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on, Leading Medical Oncologist and Hematologist Dr. Lee Schwartzberg Joins Mytesi Scientific Advisory Board for Cancer Therapy-Related Diarrhea (CTD)—An Area of Significant Concern for Diarrhea Management in the Era of Novel Targeted Agents Such as Recently Approved CDK 4/6 and Tyrosine Kinase. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer, Jaguar Health, Inc. Reports Third-Quarter 2018 Results, Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th, Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th, Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida, Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering, Knight Therapeutics and Jaguar Health Announce Strategic Partnership, New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time, Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference, Jaguar Health, Inc. Jaguar Health - Jaguar Health. Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea, Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI, Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China, Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer, Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern, Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea, Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use, Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York, Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer, Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico, Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel, Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern, Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director, Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy, Jaguar Health Appoints Carol Lizak Chief Accounting Officer, Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results, Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website, Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today, Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option, Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million, Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million, Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome, Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors, Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication, Jaguar Health, Inc. Related Link: Share your opinion and gain insight from other stock traders and investors. This was, in part, due to extraordinary items impacting earnings. 7, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on, Napo Applications Request Orphan Drug Designation for Mytesi for Congenital Diarrheal Disorders and Diarrhea Associated with Short Bowel Syndrome Pursuit of Orphan Drug Designations Parallels Jaguar’s Focus on MUMS (Minor Use and Minor Species) Indications for Canalevia in Dogs SAN FRANCISCO, Management will be available for meetings during this luncheon and networking event SAN FRANCISCO --(BUSINESS WIRE)--May 25, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for. 3, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and, National Sales Force Will Promote and Provide Samples of Mytesi™ to HIV Healthcare Providers SAN FRANCISCO--( BUSINESS WIRE )--Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally. Jaguar Receives Extension of Nasdaq Listing SAN FRANCISCO --(BUSINESS WIRE)--Apr. Shares of Jaguar Health (NASDAQ: JAGX) soared 49.3% on Friday, extending the pharmaceutical company's staggering gains since mid-November. Study Conducted in Association with Cornell University College of Veterinary Medicine and Demonstrates Significant Benefits Jaguar Plans to Launch the Prophylactic Formulation of Neonorm Calf this Year in Powder Form for Administration in Liquid SAN FRANCISCO --(BUSINESS WIRE)--Feb. Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi ™ , an FDA Approved Anti-Diarrheal Launched October 2016 that Offers a First-in-Class, Novel Mechanism of Action Jaguar to Host Investor Call Thursday, February 9th at 9:00 a.m. Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications SAN FRANCISCO --(BUSINESS WIRE)--Sep. 20, 2017-- Jaguar Health, Inc. SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- (NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging Awareness Day (NHAAD), observed annually to focus on the challenges facing the aging population with regards to HIV prevention, testing, care and treatment. Rule out infectious etiologies of diarrhea before starting MYTESI ®. Because Jaguar Health hasn't been listed for many years, the market is still learning about how the business performs. Find the latest Jaguar Health, Inc. (JAGX) stock discussion in Yahoo Finance's forum. Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has, Jaguar Targeting First Prescription Product Launch in Early 2016 SAN FRANCISCO --(BUSINESS WIRE)--Jul. SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Shares of Jaguar Health (NASDAQ: JAGX) soared 49.3% on Friday, extending the pharmaceutical company's staggering gains since mid-November. The Nasdaq Listing Council , on its own motion, will consider if the Company should have been granted a longer period within which to evidence compliance with the $1.00 per share minimum bid price requirement SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2020 /   Jaguar Health, Inc. The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04 , representing customer billings over a 51-day period SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, A significant percentage of COVID-19 recovery patients suffer from long-term diarrhea or other gastrointestinal disfunctions Non-binding terms to fund activities in Europe SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and the, SAN FRANCISCO, CA / ACCESSWIRE / November 24, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI, Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million , respectively Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE /. The offering should close on or about October 3, 2017. But as . 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, Jaguar Kicks Off Neonorm Foal TV Campaign & Neonorm Calf Radio Campaign Sales of Neonorm Calf by Jaguar’s Distributor ANIMART Up 167% in February 2017 Compared to February 2016 Napo Launches National Sales Force for Mytesi Mytesi Study Abstract Selected for Presentation as Poster Exhibition at. Announces 1-for-70 Reverse Stock Split, Jaguar Health CEO and Board Members Invest in Bridge Financing, Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020, Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet, Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders, Jaguar Health, Inc. Reports 2019 First Quarter Financial Results, Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief, Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results, Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi, Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi, Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders, Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019, With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product, Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale, Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes, Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates, Jaguar Health to Present at Biotech Showcase 2019 in San Francisco, Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance, Jaguar Health, Inc. Engages T.R. Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd. Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in Foals, Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy Science, Jaguar Animal Health to Attend the 2015 KC Animal Health Investment Forum, Jaguar Animal Health Secures Debt Financing, Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for Canalevia, KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal Health, Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical Development, Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia, Jaguar Animal Health, Inc. Added to Russell Microcap Index, Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in Calves, Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of Directors, Jaguar Animal Health, Inc. Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2019 / Jaguar Health, Inc. Company Plans to File Q3 2019 10-Q on November 14, 2019 SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday, November 14th, 2019 at 9 a.m. SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), has entered into a two-year distribution agreement ("the Agreement") with TannerGAP, Napo Pharmaceuticals , Jaguar's Subsidiary, Received Preclinical Services from the National Institute of Allergy and Infectious Diseases for the Studies SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today the completion, SAN FRANCISCO, CA / ACCESSWIRE / October 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced additional findings today from the recently completed preclinical study evaluating the effects of Mytesi ® (crofelemer) on diarrhea induced by a specific tyrosine kinase, Jaguar Health Receives $1.75 Million in Proceeds from Warrant Exercise at an Exercise Price of $1.40 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company has engaged Angel Pond Capital LLC ("Angel. ET SAN FRANCISCO --(BUSINESS WIRE)--Jan. Management will also be available to schedule meetings outside of the conference SAN FRANCISCO --(BUSINESS WIRE)--Jan. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 19, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that, Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical Development Efforts SAN FRANCISCO --(BUSINESS WIRE)--Dec. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on, SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that, A Full Analysis of the Study Data with Scoring of Squamous and Glandular Ulcers is Expected to be Available in January SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing, Statistically Significant Final Results Confirm Interim Conclusion That Crofelemer Treatment is Superior to Placebo SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class, Merger Would Allow Jaguar to Recognize an Important Revenue Stream from First-in-Class, Novel Mechanism of Action of the Anti-diarrheal Mytesi SAN FRANCISCO --(BUSINESS WIRE)--Oct. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and. Maxim Group and Jaguar to Host Web Presentation Wednesday, September 20 th at 2 p.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing, New Reps Will Target Physicians and Gastroenterologists Who Treat Large Numbers of HIV Patients SAN FRANCISCO --(BUSINESS WIRE)--Sep. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably. SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Indena S.p.A., one of the two. as Senior Vice President, Regulatory Affairs & Quality Assurance, Jaguar Health Provides Updates Regarding Company Capitalization Strategy, Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy, Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications, Jaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses Indications, Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million, Jaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility March, Jaguar Health to Host Exclusive Virtual Educational Event “Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer”, Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative, Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16, Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020, Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants, Jaguar Health Completes Transactions that Increase Stockholders' Equity Above $5,000,000, Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi), Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs, Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020, Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results, Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates, Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea, Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera, Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders, FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs, Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea, Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs, Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020, Preclinical Study Demonstrating Symptomatic Relief of Diarrhea in Dogs Receiving Neratinib in Combination with Crofelemer (Mytesi) Presented at American Association for Cancer Research Virtual Annual Meeting, On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals, Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs, Jaguar Health Sustainability Leader Interviewed on Foodie Pharmacology Podcast, Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds, Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product, Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders, Jaguar Health, Inc. Reports 2020 First Quarter Financial Results, Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates, Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in Dogs, Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate, Jaguar Health Reports 2019 Financial Results and Business Updates, Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates, Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program, Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern, Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream, Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern, Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome, Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients, Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern, Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine, Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results, Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients, Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy, Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates. SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / July 21, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Special Meeting of Stockholders of the Company (the "Special Meeting") that was held on July 21, 2020 .

Storage Baskets For Shelves, Depeche Mode - Enjoy The Silence Best Live, Sunderland To Darlington, Indo-pacific Sailfish Length, Halla Bol News | Aaj Tak, Retailing Management 10th Edition Pdf, Znotes Biology As Level, Rock Is Hell Big Cartel, Newair Wine Cooler Dual Zone Troubleshooting, Centrifugal Chiller Vs Screw Chiller,

Leave a Reply

Your email address will not be published. Required fields are marked *

Solve : *
8 × 3 =


About blog

Our blog is completely dedicated to dog life. We see a lot more in these animals than hair and paws. For us, dogs are just another family member who require special care and the right diet for health and longevity.